Storia in 5 fonti

FDA Approves Activin Signaling Inhibitor for Bone Disorder

Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 g fa

FDA Approves Activin Signaling Inhibitor for Bone Disorder

Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug

originale

healio.com

Timeline cronologica

mercoledì 19 agosto 2026·medpagetoday.com
FDA Approves Activin Signaling Inhibitor for Bone Disorder
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
mercoledì 19 agosto 2026·fiercepharma.com
Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has…

2 g fa

FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva

The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with fibrodysplasia ossificans progressiva, according to an industry press release.Garetosmab-grts…

Leggi questa versione → originale

benzinga.com2 g fa

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.

Leggi questa versione → originale

fiercepharma.com2 g fa

Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has crossed the finish line with an FDA…

Leggi questa versione → originale

endpoints.news2 g fa

FDA approves Regeneron’s drug for ultra-rare disease that turns tissue to bone

FDA approved Regeneron's Pasatru (garetosmab) for FOP, a rare disease affecting ~900 patients. Annual list price ranges $693K–$2.1M based on weight.

Leggi questa versione → originale

mercoledì 19 agosto 2026·

endpoints.news

FDA approves Regeneron’s drug for ultra-rare disease that turns tissue to bone

FDA approved Regeneron's Pasatru (garetosmab) for FOP, a rare disease affecting ~900 patients. Annual list price ranges $693K–$2.1M based on weight.

giovedì 20 agosto 2026·

healio.com

FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva

The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with fibrodysplasia ossificans progressiva, according to…

giovedì 20 agosto 2026·

benzinga.com

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.